Sean Saint is the President and Chief Executive Officer of Beta Bionics Inc., a biotechnology company revolutionizing diabetes management through its innovative bionic pancreas technology. Since joining the company in March 2021, Saint has spearheaded the commercialization of the iLet Bionic Pancreas—the first FDA-approved (August 2023) fully automated insulin delivery system that eliminates the need for manual meal announcements or carb counting. Under his leadership, Beta Bionics has expanded manufacturing capabilities, secured reimbursement pathways, and launched the device across the U.S., significantly improving glycemic control and quality of life for people with type 1 diabetes and insulin-dependent type 2 diabetes. Prior to Beta Bionics, Saint served as CEO of Tandem Diabetes Care from 2017 to 2021, where he transformed the company into a market leader by growing annual revenue from $123 million to over $500 million. He oversaw the development and launch of groundbreaking products, including the t:slim X2 insulin pump integrated with Control-IQ advanced hybrid closed-loop technology, which earned widespread adoption and clinical acclaim. Earlier in his career, Saint held senior leadership roles at Abbott Diabetes Care, including Vice President and General Manager, where he drove the global rollout of the FreeStyle Libre flash glucose monitoring system, achieving blockbuster status and transforming continuous glucose monitoring accessibility. With over two decades of experience in medical devices and diabetes care, Sean Saint brings a proven track record of innovation, commercial execution, and patient-centered strategy to Beta Bionics. His vision emphasizes scaling bionic technologies to automate diabetes therapy worldwide, forging strategic partnerships, and advancing clinical research to address unmet needs in insulin delivery.